Worth reading
61In focus
0–100. This measures how worthwhile something is to read, not how good or bad the company is.Direction
Improvement
Direction inferred from the company’s description.Scale
200
mg (dose per administration)Wording
Definitive
How definitive the wording is.Announced details
Omvoh® 200 mg subcutaneous injection Auto-InjectorOmvoh® 200 mg subcutaneous injection Syringe
Applicable field (uses covered by this announcement)
Maintenance treatment of moderate to severe ulcerative colitis in patients with an inadequate response to existing treatment
Launch dateTo be announced separately once distribution preparations are complete (specific timing not yet determined)
Relationship between the counterparty and the company
Mochida Pharmaceutical Co.,Ltd.4534
Relationship with the Company
Eli Lilly Japan K.K. is responsible for product supply and marketing authorization, while Mochida Pharmaceutical Co., Ltd. is responsible for distribution, sales and information provision activities.
In this announcement the company addresses none of Contract Value / Offering price / Impact on Business Performance.
| Item | Details |
|---|---|
| Names of Products / Services Covered | Omvoh® 200 mg subcutaneous injection Auto-Injector, Omvoh® 200 mg subcutaneous injection Syringe |
| Relationship with the Company | Eli Lilly Japan K.K. is responsible for product supply and marketing authorization, while Mochida Pharmaceutical Co., Ltd. is responsible for distribution, sales and information provision activities. |
| Launch date | To be announced separately once distribution preparations are complete (specific timing not yet determined) |
| Applicable area | Maintenance treatment of moderate to severe ulcerative colitis in patients with an inadequate response to existing treatment |
Items this document does not state (14)
CounterpartyCounterparty overviewContract ValueOffering priceContract DateAward/certification nameAwarding / certifying bodyRegistration number and expiry dateLocationLocation scaleQuantitative EffectsUsage historyImpact on Business PerformanceSource
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.To provide each patient with simpler treatment options that are easier to continue and meet diverse treatment needs.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.